Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors/Experiment 2/Signature 2

From BugSigDB
Reviewed Marked as Reviewed by Folakunmi on 2024-2-15

Curated date: 2021/01/10

Curator: William Lam

Revision editor(s): Atrayees, WikiWorks, Folakunmi

Source: Figure 2C

Description: Comparsion of patients with partial progressive survival free more than 3 months and less than 3 in fecal samples of patients (excluding those treated with antibiotics) with non-small cell lung cell lung carcinoma (NSCLC) or renal cell carcinoma (RCC) reponse at 3 months of PD-1 monoclonal antibodies (mAB) treatment

Abundance in Group 1: decreased abundance in Progressive -Free- Survival more than 30 days

NCBI Quality ControlLinks
Anaerotruncus colihominis
Bacillota bacterium
Erysipelotrichaceae
Eubacteriales
Lachnospiraceae
Parabacteroides distasonis
unclassified Eubacteriales

Revision editor(s): Atrayees, WikiWorks, Folakunmi